Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study of Recombinant Human Arylsulfatase A (HGT-1111) in Late Infantile MLD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject's legally authorized guardian(s) must provide signed, informed consent prior to performing any study-related activities (Trial-related activities are any procedures that would not have been performed during normal management of the subject)~2. Completion of study HGT-MLD-048 (NCT00633139)~3. The subject and his/her guardian(s) must have the ability to comply with the protocol~Exclusion Criteria:~1. Spasticity so severe to inhibit transportation~2. Presence of known clinically significant cardiovascular, hepatic, pulmonary or renal disease or other medical condition that, in the opinion of the Investigator, would preclude participation in the trial~3. Any other medical condition or serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the trial

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- HGT-1111 100 U/kg (Type: EXPERIMENTAL): None
- HGT-1111 200 U/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).